
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon has demonstrated strong business growth, with gross business awards increasing by 11% on a sequential basis, supported by significant wins from biotech customers and the expansion of existing partnerships with large pharmaceutical companies. The company has successfully met or exceeded most financial targets related to its PRA acquisition, positioning itself favorably against ongoing funding environment uncertainties, which highlights its robust client and business mix. Additionally, Icon is well-positioned to capitalize on the growth within the contract research organization (CRO) market, indicating enhanced capabilities to accelerate clinical trial research.
Bears say
The financial analysis indicates a negative outlook for Icon's stock, primarily due to an expected decline in EBITDA margins, which are now anticipated to be in the high-19% range compared to previous expectations of approximately 20%. Additionally, the company faces significant downside risks, including potential slowdowns in clinical trial activity due to pharmaceutical reprioritization and uncertainties in biotech funding. These factors, combined with inflationary pressures and a general slowdown in pharmaceutical R&D spending, contribute to concerns over Icon's future financial performance.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares